LLY vs NVO Comparison: AI Score, Valuation, Performance and Upside
LLY holds the edge across 3 of 5 key metrics in this comparison. LLY has delivered stronger 1-year price return (+44.49% vs -28.70%), though NVO trades at the lower forward P/E (2.20x vs 24.71x). Analyst consensus implies meaningfully more upside for LLY (+10.94%) than for NVO (-1.31%).
| Metric | LLY | NVO |
|---|---|---|
| AI score | 73.1 | 39.9 |
| AI rank | #24 | #1048 |
| Latest close | $1,102.08 | $47.42 |
| 1M return | +3.48% | +5.47% |
| 6M return | +2.86% | +2.20% |
| 1Y return | +44.49% | -28.70% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | LLY | NVO |
|---|---|---|
| 1Y ago | $14.3K (+43.0%) started 2025-06-23 | $7.47K (-25.3%) started 2025-06-23 |
| 5Y ago | $55.04K (+450.4%) started 2021-06-23 | $14.45K (+44.5%) started 2021-06-23 |
| 10Y ago | $205.43K (+1954.3%) started 2016-06-23 | $28.87K (+188.7%) started 2016-06-23 |
Hypothetical — past performance does not guarantee future results.
| Metric | LLY | NVO |
|---|---|---|
| Market cap | $979.64B | $209.92B |
| Trailing P/E | 39.07 | 10.93 |
| Forward P/E | 24.71 | 2.20 |
| Price/Sales | 14.10 | 0.64 |
| EV/Revenue | 14.09 | 1.02 |
| Analyst target | $1,218.72 | $46.80 |
| Target upside | +10.94% | -1.31% |
| Metric | LLY | NVO |
|---|---|---|
| Revenue growth | 55.50% | 24.00% |
| Earnings growth | 169.90% | 67.10% |
| EPS growth | +169.90% | +67.10% |
| FCF margin | +12.67% | -3.67% |
| Operating margin | 49.39% | N/A |
| Profit margin | 34.99% | 37.21% |
| ROIC proxy | 107.46% | 71.40% |
| Return on equity | 107.46% | 71.40% |
| Dividend yield | 0.63% | 3.80% |
| Beta | 0.52 | 0.35 |
| Debt/equity | 139.01 | 72.09 |
| Current ratio | 1.50 | 0.79 |
| Quick ratio | 0.72 | 0.54 |
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | LLY | NVO |
|---|---|---|---|
| 1Y | Growth | +43.01% | -28.70% |
| CAGR | +43.18% | -28.71% | |
| Sharpe ratio | 1.02 | -0.47 | |
| Max drawdown | 23.31% | 49.17% | |
| Max daily drop | 14.14% | 21.83% | |
| Max wkly drop | 17.93% | 33.45% | |
| 5Y | Growth | +428.42% | +29.31% |
| CAGR | +39.53% | +5.28% | |
| Sharpe ratio | 1.06 | 0.21 | |
| Max drawdown | 34.48% | 74.70% | |
| Max daily drop | 14.14% | 21.83% | |
| Max wkly drop | 17.93% | 33.45% | |
| 10Y | Growth | +1639.32% | +123.61% |
| CAGR | +33.07% | +8.38% | |
| Sharpe ratio | 0.95 | 0.28 | |
| Max drawdown | 34.48% | 74.70% | |
| Max daily drop | 14.14% | 21.83% | |
| Max wkly drop | 17.93% | 33.45% |
| Category | LLY | NVO |
|---|---|---|
| Company | LLY | NVO |
| Sector | Healthcare | N/A |
| Industry | Drug Manufacturers - General | N/A |
| Core business | N/A | N/A |
| Investor focus | N/A | N/A |
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.